Lipid lowering with PCSK9 inhibitors (Q38222649)

31 August 2017

title

Lipid lowering with PCSK9 inhibitors (English)

1 reference

31 August 2017

Razvan T Dadu

1

1 reference

31 August 2017

Christie M Ballantyne

series ordinal

2

1 reference

31 August 2017

language of work or name

English

0 references

publication date

24 June 2014

1 reference

Nature Reviews Cardiology

31 August 2017

published in

1 reference

31 August 2017

volume

11

1 reference

31 August 2017

issue

10

1 reference

31 August 2017

page(s)

563-575

1 reference

Sources of variability in measurements of cardiac troponin T in a community-based sample: the atherosclerosis risk in communities study

31 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.84

Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.84

Low density lipoprotein cholesterol, statins and cardiovascular events: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.84

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.84

Intensive versus moderate lipid lowering with statins after acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.84

Efficacy and safety of rosuvastatin therapy for children with familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.84

Clinical characterization and molecular mechanisms of statin myopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.84

Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.84

Statins and the risk of new-onset diabetes: a review of recent evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.84

Mutations in PCSK9 cause autosomal dominant hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.84

Mutations and polymorphisms in the proprotein convertase subtilisin kexin 9 (PCSK9) gene in cholesterol metabolism and disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.84

Proprotein convertase subtilisin kexin 9: the third locus implicated in autosomal dominant hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.84

Genetic causes of familial hypercholesterolaemia in patients in the UK: relation to plasma lipid levels and coronary heart disease risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.84

Mutational analysis in UK patients with a clinical diagnosis of familial hypercholesterolaemia: relationship with plasma lipid traits, heart disease risk and utility in relative tracing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.84

PCSK9 dominant negative mutant results in increased LDL catabolic rate and familial hypobetalipoproteinemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.84

A novel loss of function mutation of PCSK9 gene in white subjects with low-plasma low-density lipoprotein cholesterol

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.84

Sequence variations in PCSK9, low LDL, and protection against coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.84

PCSK9 R46L, low-density lipoprotein cholesterol levels, and risk of ischemic heart disease: 3 independent studies and meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.84

The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.84

Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.84

Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. Law MR, Wald NJ, Rudnicka AR. BMJ 2003; 326: 1407-408.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.84

Biomedicine. Lowering LDL--not only how low, but how long?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.84

Variation in PCSK9, low LDL cholesterol, and risk of peripheral arterial disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.84

Longitudinal association of PCSK9 sequence variations with low-density lipoprotein cholesterol levels: the Coronary Artery Risk Development in Young Adults Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.84

Molecular biology of PCSK9: its role in LDL metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.84

A common PCSK9 haplotype, encompassing the E670G coding single nucleotide polymorphism, is a novel genetic marker for plasma low-density lipoprotein cholesterol levels and severity of coronary atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.84

NARC-1/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.84

Proprotein convertase subtilisin/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.84

Circulating proprotein convertase subtilisin kexin type 9 has a diurnal rhythm synchronous with cholesterol synthesis and is reduced by fasting in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.84

Serum PCSK9 is associated with multiple metabolic factors in a large Han Chinese population

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.84

The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.84

Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.84

Clinical aspects of PCSK9.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.84

Proprotein convertase subtilisin/kexin type 9 (PCSK9): from structure-function relation to therapeutic inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.84

Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.84

Secreted proprotein convertase subtilisin/kexin type 9 reduces both hepatic and extrahepatic low-density lipoprotein receptors in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.84

Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.84

The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.84

Overexpression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.84

Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.84

Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.84

High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.84

A proteolytic pathway that controls the cholesterol content of membranes, cells, and blood

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.84

Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.84

Sterols regulate cycling of SREBP cleavage-activating protein (SCAP) between endoplasmic reticulum and Golgi

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.84

Missense mutations in the PCSK9 gene are associated with hypocholesterolemia and possibly increased response to statin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.84

Pharmacological strategies for lowering LDL cholesterol: statins and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.84

A locked nucleic acid antisense oligonucleotide (LNA) silences PCSK9 and enhances LDLR expression in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.84

Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.84

PCSK9 LNA antisense oligonucleotides induce sustained reduction of LDL cholesterol in nonhuman primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.84

PCSK9 Inhibitors: potential in cardiovascular therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.84

Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.84

Potential of proprotein convertase subtilisin/kexin type 9 based therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.84

A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.84

An anti-PCSK9 antibody reduces LDL-cholesterol on top of a statin and suppresses hepatocyte SREBP-regulated genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.84

A PCSK9-binding antibody that structurally mimics the EGF(A) domain of LDL-receptor reduces LDL cholesterol in vivo1[S]

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.84

Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.84

Effect of a monoclonal antibody to PCSK9 on LDL cholesterol

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.84

Effects of AMG 145 on low-density lipoprotein cholesterol levels: results from 2 randomized, double-blind, placebo-controlled, ascending-dose phase 1 studies in healthy volunteers and hypercholesterolemic subjects on statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.84

Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.84

Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised con

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.84

Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.84

Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 In

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.84

Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.84

AMG145, a monoclonal antibody against proprotein convertase subtilisin kexin type 9, significantly reduces lipoprotein(a) in hypercholesterolemic patients receiving statin therapy: an analysis from the LDL-C Assessment with Proprotein Convertase Sub

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.84

A 52-week placebo-controlled trial of evolocumab in hyperlipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.84

ACC/AHA/NHLBI clinical advisory on the use and safety of statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.84

Safety and effect of very low levels of low-density lipoprotein cholesterol on cardiovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.84

Cardiovascular event reduction and adverse events among subjects attaining low-density lipoprotein cholesterol <50 mg/dl with rosuvastatin. The JUPITER trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuv

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.84

Friedewald-estimated versus directly measured low-density lipoprotein cholesterol and treatment implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.84

Friedewald equation underestimates low-density lipoprotein cholesterol at low concentrations in young people with and without Type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.84

The Friedewald formula underestimates LDL cholesterol at low concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.84

Statin therapy and the risk of intracerebral hemorrhage: a meta-analysis of 31 randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.84

Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.84

Cochrane review on 'Statins for the treatment of dementia'.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.84

Circulating proprotein convertase subtilisin/kexin 9 (PCSK9) regulates VLDLR protein and triglyceride accumulation in visceral adipose tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.84

PCSK9-deficient mice exhibit impaired glucose tolerance and pancreatic islet abnormalities.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.84

PCSK9 impedes hepatitis C virus infection in vitro and modulates liver CD81 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.84

Genome-wide expression analysis of cells expressing gain of function mutant D374Y-PCSK9.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.84

A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.84

Clinical use of genetic typing in human lipid disorders

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.84

Serum proprotein convertase subtilisin kexin type 9 is correlated directly with serum LDL cholesterol

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.84

Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.84

Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.84

Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.84

Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.84

2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.84

High-dose atorvastatin after stroke or transient ischemic attack

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.84

Statins for the treatment of dementia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.84

The effect of low- and high-density lipoprotein cholesterol on steroid hormone production and ACTH-induced differentiation of rat adrenocortical cells in primary culture

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.84

Effects of mevinolin, an inhibitor of cholesterol synthesis, on the morphology and function of differentiating and differentiated rat adrenocortical cells in primary culture

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.84

The molecular genetic basis and diagnosis of familial hypercholesterolemia in Denmark.

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24958078

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Efficacy and Safety of Bococizumab (RN316/PF-04950615), a Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9, in Hypercholesterolemic Japanese Subjects Receiving a Stable Dose of Atorvastatin or Treatment-Naive　- Results From

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24958078

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Proprotein convertase subtilisin/kexin type 9 (PCSK9) affects gene expression pathways beyond cholesterol metabolism in liver cells

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24958078

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/NRCARDIO.2014.84

1 reference

31 August 2017

1 reference